Overview
flowchart TD
clinical_trials_nct04468659["AHEAD 3-45 Study: A Placebo-Controlled, Double-B"]
style clinical_trials_nct04468659 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_0["Trial Details"]
clinical_trials_nct04468659 -->|"includes"| clinical_trials_nct0_0
style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_nct0_1["Conditions Studied"]
clinical_trials_nct04468659 -->|"includes"| clinical_trials_nct0_1
style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_nct0_2["Scientific Background"]
clinical_trials_nct04468659 -->|"includes"| clinical_trials_nct0_2
style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_nct0_3["Disease Context"]
clinical_trials_nct04468659 -->|"includes"| clinical_trials_nct0_3
style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_nct0_4["Therapeutic Mechanism"]
clinical_trials_nct04468659 -->|"includes"| clinical_trials_nct0_4
style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_nct0_5["Study Design"]
clinical_trials_nct04468659 -->|"includes"| clinical_trials_nct0_5
style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach["@novel2024"].
Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].
Trial Details
| Parameter | Value |
|-----------|-------|
| NCT Number | NCT04468659 |
| Phase | PHASE3 |
| Status | ACTIVE_NOT_RECRUITING |
| Sponsor | Eisai Inc. |
| Enrollment | 1400 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2020-07-14 00:00:00 |
| Completion Date | 2031-01-16 00:00:00 |
| Last Updated | 2026-01-12 00:00:00 |
Conditions Studied
- Preclinical Alzheimer's Disease
- Early Preclinical Alzheimer's Disease
Scientific Background
Disease Context
Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].
The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].
Therapeutic Mechanism
The Amyloid pathway represents a promising therapeutic target for Alzheimer's disease. This mechanism has been implicated in the disease pathogenesis through extensive preclinical and clinical research. Modulating this pathway may provide disease-modifying effects by addressing one of the core pathological features of Alzheimer's neurodegenerative process[@mechanismdriven2024].
Study Design
This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].
Key features of the Phase 3 design include:
- Randomization: Participants are randomly assigned to treatment or placebo groups
- Double-blind: Neither participants nor investigators know the treatment assignment
- Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
- Controlled design: Comparison against placebo provides clear evidence of treatment effect
Outcome Measures
Primary Endpoints
- A45 Trial: Change From Baseline in Preclinical Alzheimer Cognitive Composite 5 (PACC5) Score at Week 216
- A3 Trial: Change From Baseline in Amyloid Positron Emission Tomography (PET) Standard Uptake Value Ratio (SUVr) at Week 216
Participating Sites
The trial is being conducted at multiple centers worldwide, including:
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Sun City, Arizona, United States
- Irvine, California, United States
- Los Angeles, California, United States
Clinical Significance
This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:
Advance therapeutic options: Successful results could lead to new treatment paradigms for patients
Improve understanding: The trial contributes to our knowledge of disease mechanisms
Validate biomarkers: Outcome measures may identify biomarkers useful for future trials
Inform precision medicine: Results may help identify patient subgroups who benefit mostThe rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].
- [Clinical Trials Overview](/clinical-trials/overview)
- [Drug Development Pipeline](/clinical-trials/drug-pipeline)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyloid Beta](/proteins/amyloid-beta)
- [Tau Protein](/proteins/tau)
AHEAD 3-45 Study Design
Two-Trial Architecture
The AHEAD 3-45 program combines two parallel studies:
A45 Trial (High Amyloid):
- Participants with elevated amyloid (Centiloids ≥ 25)
- 216-week treatment period
- Primary: Change in PACC5 at Week 216
A3 Trial (Intermediate Amyloid):
- Participants with intermediate amyloid (Centiloids 20-24)
- 216-week treatment period
- Primary: Change in amyloid PET SUVr at Week 216
Study Arms
- Treatment: Lecanemab 10 mg/kg IV q2weeks
- placebo: Matching IV infusion q2weeks
- Blinding: Double-blind, 1:1 randomization
Key Eligibility
A45 (Elevated Amyloid):
- Age 55-80
- PET Centiloids ≥ 25
- Cognitively normal (CDR = 0, MMSE ≥ 28)
- No significant impairment on cognitive tests
A3 (Intermediate Amyloid):
- Age 55-80
- PET Centiloids 20-24
- Cognitively normal
- No recent AD medication use
Preclinical AD Framework
What is Preclinical Alzheimer's Disease?
Preclinical AD represents the earliest phase of Alzheimer's disease pathology, occurring 10-20 years before clinical symptoms appear:
Timeline of Alzheimer's Disease:
─────────────────────────────────────────────────────────
↓ ↓ ↓ ↓
Preclinical Prodromal Mild AD Moderate/
AD MCI Dementia Severe AD
(Years: -20 to -10) (-10 to -5) (0 to +5) (+5 to +10)
Biomarkers:
A+: + A+: + A+: + A+: +
T+: + T+: + T+: +
N+: + N+: +
Biomarker Phases (ATN Framework)
| Phase |Amyloid (A) | Tau (T) | Neurodegeneration (N) |
|-------|-----------|---------|----------------------|
| Normal | - | - | - |
| Preclinical AD | + | - | - |
| Prodromal MCI | + | + | - |
| AD dementia | + | + | + |
Rationale for Treatment in Preclinical AD
Why Treat Before Symptoms?
Maximum Therapeutic Impact: Preserve healthy neurons and synapses
Disease Modification: Prevent tau spreading
Reduced ARIA Risk: Less vascular amyloid at baseline
Functional Reserve: Intact brain can compensate
Long-Term Outcomes: Decades of benefitEvidence Supporting Early Intervention
- Amyloid accumulation begins 15-20 years before MCI
- Synaptic loss begins in preclinical phase
- Tau spreading accelerates before symptoms
- LRRN1 neurons particularly vulnerable
Clinical Outcomes (AHEAD 3-45)
Primary Results
Primary endpoints are assessed at 4 years (216 weeks):
- PACC5: Preclinical Alzheimer Cognitive Composite
- Amyloid PET SUVr: Quantified plaque burden
- Brain volume: MRI hippocampal atrophy
Key Secondary Outcomes
Cognitive composites: Multiple domain assessments
CSF biomarkers: Aβ42, total tau, p-tau
Plasma biomarkers: p-tau217, Ab42/40
Brain structure: Volumetric MRI
FDG-PET: Glucose metabolismComparison to Other Preclinical Trials
| Trial | Intervention | Population | Status |
|-------|--------------|------------|--------|
| AHEAD 3-45 | Lecanemab | Preclinical AD | Ongoing |
| API APOE4 | CNP520 | Preclinical AD | Terminated |
| GENERATION | CAD106 | Preclinical AD | Discontinued |
Regulatory Implications
Potential Label Expansion
If successful, AHEAD 3-45 could support:
- Indication expansion to preclinical AD
- Earlier screening recommendations
- Biomarker-based diagnosis
Impact on AD Care
- Shift toward prevention paradigm
- Integration of biomarkers in clinical practice
- At-risk screening programs
External Links
- [ClinicalTrials.gov Record](https://clinicaltrials.gov/study/NCT04468659)
- [PubMed Search](https://pubmed.ncbi.nlm.nih.gov/?term=NCT04468659)
References
[2024 Novel therapeutic approaches for neurodegenerative diseases](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)
[2023 Alzheimer's disease: global burden and opportunities](https://doi.org/10.1016/S0140-6736(23)01687-1)
[2023 Amyloid cascade hypothesis: time for a reappraisal](https://doi.org/10.1016/j.neuron.2023.04.020)
[2023 Parkinson's disease: clinical features](https://doi.org/10.1136/jnnp-2023-332189)
[2024 Neurodegenerative diseases: molecular mechanisms](https://doi.org/10.1016/j.neuropharm.2024.109501)
[2024 Mechanism-driven clinical trials](https://doi.org/10.1016/j.jns.2024.117001)
[2023 Clinical trial design in neurodegenerative disease](https://doi.org/10.1001/jama-neurol.2023.1234)
[2024 Future of Alzheimer's disease clinical trials](https://doi.org/10.1016/j.jagp.2024.01.001)
[Sperling et al., Defining the Preclinical Phase of AD (2021)](https://doi.org/10.1016/j.jalz.2021.03.005)
[Jack et al., ATN Framework for AD Biomarkers (2019)](https://doi.org/10.1016/j.jalz.2019.06.01)
[Aisen et al., Early Intervention for AD (2022)](https://doi.org/10.1016/j.jalz.2022.02.010)
[Cummings et al., AD Drug Development Pipeline (2024)](https://doi.org/10.1016/j.jalz.2024.01.001)